Back to Search
Start Over
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
- Source :
-
Clinical genitourinary cancer [Clin Genitourin Cancer] 2016 Feb; Vol. 14 (1), pp. e19-24. Date of Electronic Publication: 2015 Aug 15. - Publication Year :
- 2016
-
Abstract
- Unlabelled: Several adverse events (AEs) are known to be commonly observed during treatment with different tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC) patients. However, no significant correlation appears present in the profiles of such AEs between first- and second-line TKI therapies. Therefore, a second-line targeted agent for patients with mRCC could be selected irrespective of the AE profile during first-line TKI therapy.<br />Background: Several adverse events (AEs) commonly observed during treatment with different tyrosine kinase inhibitors (TKIs). The objective of the present study was to investigate whether the appearance of such AEs during treatment with first-line TKIs significantly affects the occurrence of AEs during second-line TKI therapy for patients with metastatic renal cell carcinoma (mRCC).<br />Patients and Methods: The present study included 154 consecutive patients with mRCC treated with second-line TKIs after the discontinuation of first-line TKIs. The association of AEs, including diarrhea, fatigue, hand-foot syndrome, hypertension, and hypothyroidism, between first- and second-line therapies was analyzed in these 154 patients.<br />Results: For all 5 AEs assessed in the present study, the proportion of patients experiencing AEs or those grade ≥ 3 during second-line TKI therapy was not significantly different among the following 3 groups: patients without AEs, those with grade ≤ 2 AEs, and those with grade ≥ 3 AEs during first-line TKI therapy. Furthermore, no significant difference was seen in progression-free or overall survival after the introduction of second-line TKIs between patients with and without grade ≥ 3 AEs during treatment with first-line TKIs.<br />Conclusion: The incidence of AEs or grade ≥ 3 AEs during second-line TKI therapy are not dependent on the profiles of AEs during first-line TKI therapy in patients with mRCC. Therefore, AEs that occur during first-line TKI therapy should not affect the selection of second-line targeted agents for patients with mRCC.<br /> (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Agents therapeutic use
Axitinib
Carcinoma, Renal Cell mortality
Carcinoma, Renal Cell secondary
Female
Humans
Imidazoles adverse effects
Imidazoles therapeutic use
Indazoles adverse effects
Indazoles therapeutic use
Indoles adverse effects
Indoles therapeutic use
Kaplan-Meier Estimate
Kidney Neoplasms mortality
Kidney Neoplasms pathology
Lung Neoplasms mortality
Lung Neoplasms secondary
Male
Middle Aged
Niacinamide adverse effects
Niacinamide analogs & derivatives
Niacinamide therapeutic use
Phenylurea Compounds adverse effects
Phenylurea Compounds therapeutic use
Prognosis
Protein Kinase Inhibitors therapeutic use
Pyrroles adverse effects
Pyrroles therapeutic use
Retrospective Studies
Sorafenib
Sunitinib
Antineoplastic Agents adverse effects
Carcinoma, Renal Cell drug therapy
Kidney Neoplasms drug therapy
Lung Neoplasms drug therapy
Protein Kinase Inhibitors adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1938-0682
- Volume :
- 14
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Clinical genitourinary cancer
- Publication Type :
- Academic Journal
- Accession number :
- 26382221
- Full Text :
- https://doi.org/10.1016/j.clgc.2015.08.002